{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-070127","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.701981+00:00","generated_at":"2026-06-22T03:18:02.699182+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OptimizeRx Q3 revenue $15.1M, down 6% YoY; GAAP loss $0.19/share; FY guidance reaffirmed","bullets":["Revenue $15.1M (-6% YoY, +8% QoQ); gross margin improved to 62% from 56%.","GAAP net loss $3.5M ($0.19 per share); non-GAAP net income $1.3M ($0.07 per share).","Operating cash flow $7.9M in first nine months; cash & investments $78.8M.","FY2022 guidance reiterated: revenue $62M-$68M, gross margin 59%-62%.","Repurchased 1.1M shares YTD at average price of $16.70 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-070127","json":"https://secwatch.observer/filing/0001213900-22-070127.json","markdown":"https://secwatch.observer/filing/0001213900-22-070127.md","text":"https://secwatch.observer/filing/0001213900-22-070127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/0001213900-22-070127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/ea168208-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:18:02.699182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae74e12dd314c607d256d3ea5480518f50f60796","claim":"OptimizeRx Corp reported third quarter ended September 30, 2022 results: revenue $15.1 million, net income $3.5 million or $(0.19) per basic and diluted share, EPS $(0.19). Guidance reaffirmed.","evidence_excerpt":"OptimizeRx Reports Third Quarter 2022 Financial Results - Q3 Revenue of $15.1 million, down 6% year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/0001213900-22-070127-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$15.1 million"},{"label":"Net income","value":"$3.5 million or $(0.19) per basic and diluted share"},{"label":"EPS","value":"$(0.19)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}